Fasting Insulin Deep Dive: The Early Warning Signal for Metabolic Drift

What fasting insulin actually measures

Fasting insulin is the amount of insulin circulating in blood after roughly eight to twelve hours without food, measured from the same draw as fasting glucose. Insulin is the hormone that moves glucose out of the bloodstream and into muscle, fat, and liver cells, and the amount your pancreas needs to secrete to do that job depends on how sensitive those cells are to insulin's signal. When cells are highly sensitive, a small amount of insulin is enough. When cells become resistant, the pancreas has to secrete progressively more insulin to achieve the same effect.

That distinction is why fasting insulin and fasting glucose measure different things. Glucose reflects whether blood sugar is currently under control. Insulin reflects how hard the pancreas is working to keep it there. Two people can have an identical fasting glucose of 90 mg/dL, one because their body needs very little insulin to hold it there and the other because their pancreas is compensating with two or three times as much insulin to achieve the same number. The HOMA-IR calculation combines both values into a single insulin resistance estimate, using the formula developed by David Matthews and colleagues at Oxford in a 1985 paper in Diabetologia, but the raw fasting insulin number on its own already carries information that glucose alone does not.

Gerald Reaven's 1988 Banting Lecture in Diabetes, which introduced what he called Syndrome X, made the case that insulin resistance and the compensatory hyperinsulinemia it produces sit upstream of a whole cluster of problems: elevated triglycerides, low HDL, higher blood pressure, and eventually glucose intolerance itself. Reading fasting insulin in isolation misses that broader picture, which is why it is more useful as one piece of a wider metabolic panel than as a single pass or fail test.

Why insulin rises before glucose does

The reason fasting insulin can serve as an early signal comes down to how the pancreas responds to developing insulin resistance. Gordon Weir and Susan Bonner-Weir described this progression in a widely cited 2004 paper in Diabetes, outlining five stages of evolving beta-cell function on the way to diabetes. In the earliest stage, the beta cells of the pancreas increase insulin output to compensate for rising insulin resistance, and that compensation is often strong enough to hold fasting glucose fully in the normal range. Glucose only starts drifting upward in later stages, once the beta cells can no longer keep pace with demand.

Christopher Nolan and Marc Prentki argued for taking this compensation phase seriously in a 2019 paper in Diabetes and Vascular Disease Research, proposing that insulin hypersecretion itself, not just resistance, deserves more clinical attention as an early and modifiable stage of metabolic disease. Their broader point is that by the time glucose or HbA1c cross a diagnostic threshold, the underlying insulin resistance driving that rise has usually been building for years. Fasting insulin is one of the more direct ways to see that earlier stage while glucose still looks unremarkable.

This is also the pattern Joseph Kraft described in his 1975 paper in Laboratory Medicine, based on insulin assays run alongside standard glucose tolerance tests. A 2016 reanalysis of his full database by Catherine Crofts and colleagues, published in Diabetes Research and Clinical Practice, examined more than 7,000 of these paired tests and found that hyperinsulinemia was present in over 80 percent of the sample overall, and in nearly 75 percent of people whose glucose tolerance test came back completely normal. Kraft referred to this pattern as diabetes in situ, meaning the insulin abnormality that typically precedes a diabetes diagnosis was already detectable, just not yet visible on a standard glucose test.

How to read a fasting insulin number

There is no single, universally agreed reference range for fasting insulin the way there is for fasting glucose, partly because insulin assays differ between labs and are not as tightly standardized. Most conventional lab reference ranges list fasting insulin as normal up to somewhere around 25 mIU/L, but metabolic researchers who study early insulin resistance generally consider that range too permissive, since compensatory hyperinsulinemia is already common well below it. That gap between a technically normal lab result and an early warning sign is exactly why fasting insulin needs context rather than a single pass or fail cutoff.

Because a standardized fasting insulin assay is not always available, Thomas McLaughlin and colleagues, in a 2003 study in Annals of Internal Medicine, validated a surrogate marker built from a standard lipid panel: a triglyceride to HDL cholesterol ratio of 3.0 or higher reliably flagged overweight, insulin resistant individuals in their sample, using an intravenous insulin sensitivity test as the reference standard. That ratio will not substitute for a direct insulin measurement in every population, but it is a useful, widely available cross-check when fasting insulin looks borderline.

Fasting insulin also fluctuates with recent food intake, illness, sleep loss, and simple assay variability, which is why one value on one day is far less informative than a trend measured a few times a year alongside glucose, HbA1c, and a lipid panel. Wearable data can also flag related patterns, such as elevated resting heart rate or reduced HRV, that often accompany rising insulin resistance, though none of those signals replace an actual blood draw.

The normal glucose misconception

This misconception matters because it is also why fasting insulin is not part of standard diagnostic criteria. The American Diabetes Association's Standards of Care in Diabetes defines prediabetes and diabetes using fasting glucose, a 75 gram oral glucose tolerance test, and HbA1c, with no fasting insulin threshold included. That is a reasonable choice for a population-level diagnostic standard, since insulin assays vary more between labs than glucose assays do, but it also means a clinician following the guideline to the letter will not flag someone in the compensation stage that Weir and Bonner-Weir described, because glucose has not moved yet.

The same logic applies at the other end of the metabolic spectrum. Francesco Facchini, Nancy Hua, Fahim Abbasi, and Gerald Reaven followed 208 healthy, non-obese adults for an average of 6.3 years in a 2001 study in The Journal of Clinical Endocrinology and Metabolism and found that baseline insulin resistance predicted later hypertension, coronary heart disease, and type 2 diabetes, in people who were not overweight and would not have been flagged by weight alone. Insulin resistance and the elevated insulin that comes with it are not conditions reserved for people who are visibly overweight.

What to do about a high or rising fasting insulin

Because early insulin resistance is largely driven by lifestyle factors that are directly modifiable, most of the useful response to a rising fasting insulin trend does not require waiting for a clinical diagnosis first.

Frequently asked questions